Premature ovarian insufficiency (POI) affects approximately 1% of women under 40 — roughly 1 in 100 — yet for a condition that abruptly ends reproductive potential and accelerates long-term health risks, it remains remarkably under-recognized. Conventional management with hormone replacement therapy (HRT) protects bone and cardiovascular health but does not restore ovarian function, and donor oocytes are the only proven path to pregnancy. Mesenchymal stem cell (MSC) therapy has emerged as an investigational strategy that targets the root pathology — follicular depletion, granulosa cell apoptosis, and ovarian stromal dysfunction — rather than simply replacing the hormones the ovary can no longer produce [1].

What the diagnosis means. POI is defined by amenorrhea or oligomenorrhea for at least 4 months, elevated follicle-stimulating hormone (FSH > 25 IU/L on two occasions > 4 weeks apart), and low estradiol, occurring before age 40. Unlike natural menopause — which unfolds gradually over years — POI can strike abruptly, sometimes within months, and approximately 5–10% of women experience spontaneous intermittent ovarian activity and, rarely, pregnancy after diagnosis [2]. This residual follicular activity is the biological foothold that MSC therapy attempts to amplify and sustain.

Where conventional treatment falls short. HRT replaces estrogen and progesterone — protecting against osteoporosis, cardiovascular disease, and vasomotor symptoms — but it does not recruit dormant follicles, reverse granulosa cell loss, or restore the complex paracrine signaling network of a healthy ovary. In vitro fertilization with donor oocytes achieves pregnancy rates of 50–60% per cycle but does not provide a genetically related child, which many patients desire [3]. The unmet need is staggering: a therapy that restores endogenous ovarian function, enabling both hormone production and potential fertility from the patient's own oocytes.

What Is Premature Ovarian Insufficiency? A Definition with Precision

Premature ovarian insufficiency is the loss of normal ovarian function before age 40, characterized by depleted or dysfunctional ovarian follicles, elevated gonadotropins, and hypoestrogenism. The term "insufficiency" is deliberate: unlike "premature menopause" — which implies permanent cessation — POI acknowledges that some women retain intermittent ovarian activity, and up to 10% may conceive spontaneously. The condition spans a spectrum from occult POI (regular menses but reduced fertility) through biochemical POI (irregular cycles with elevated FSH) to overt POI (amenorrhea with full hormonal picture) [4].

The causes are heterogeneous. Approximately 10–15% of cases are genetic — Turner syndrome (45,X), Fragile X premutation (FMR1), and mutations in genes regulating folliculogenesis (FOXL2, BMP15, GDF9, NOBOX, FIGLA). Autoimmune oophoritis accounts for another 4–30% of cases, often co-occurring with Addison's disease, thyroid autoimmunity, or polyglandular autoimmune syndromes. Iatrogenic causes — chemotherapy (especially alkylating agents like cyclophosphamide), pelvic radiation, and bilateral oophorectomy — are increasingly common as cancer survival rates improve. Yet in roughly 70–90% of cases, no cause is identified; these are classified as idiopathic [5].

The consequences extend beyond fertility. Chronic estrogen deficiency accelerates bone loss (osteoporosis risk is 2–3 times higher), cardiovascular aging (endothelial dysfunction, adverse lipid profiles), cognitive changes, and urogenital atrophy. The psychological burden — grief over lost fertility, anxiety about accelerated aging, social isolation — is profound and often under-treated [6].

The Pathophysiology of POI: Why Ovaries Stop Functioning

POI results from a breakdown in the delicate balance between follicular recruitment, survival, and atresia — the programmed cell death that normally eliminates 99.9% of follicles over a woman's reproductive lifespan. In POI, this balance tilts disastrously toward accelerated depletion. Understanding the cellular mechanisms reveals precisely where MSC therapy may intervene [7].

Follicular depletion via apoptosis. Granulosa cells — the somatic cells that surround and nourish each oocyte — are the primary site of apoptosis in POI. When granulosa cells die, the oocyte they support is lost. Chemotherapy agents activate the PI3K/AKT pathway in primordial follicles, paradoxically triggering massive synchronous activation and subsequent burnout — a phenomenon called the "burnout effect." Alkylating agents like cyclophosphamide also directly damage oocyte DNA. The result is a follicle pool that shrinks years or decades ahead of schedule [8].

Oxidative stress and mitochondrial dysfunction. The ovarian stroma in POI shows elevated reactive oxygen species (ROS), depleted antioxidant defenses (SOD, glutathione peroxidase), and mitochondrial DNA damage. Oocytes are exquisitely sensitive to oxidative injury — they have limited capacity for DNA repair and rely heavily on surrounding cumulus cells for antioxidant support. When oxidative stress overwhelms this support network, follicular atresia accelerates [9].

Immune dysregulation. In autoimmune POI, CD4+ and CD8+ T lymphocytes infiltrate the ovarian stroma and peri-follicular regions, releasing pro-inflammatory cytokines (IFN-γ, TNF-α, IL-1β) that directly damage granulosa cells and theca cells. Autoantibodies targeting steroidogenic enzymes (21-hydroxylase, 17α-hydroxylase, P450 side-chain cleavage enzyme) and the zona pellucida have been identified in subsets of patients. The ovarian microenvironment becomes hostile to follicular survival [10].

Vascular insufficiency and stromal fibrosis. The ovarian stroma requires a rich microvascular network to deliver oxygen, nutrients, and hormonal signals to developing follicles. In POI, reduced VEGF expression, capillary rarefaction, and progressive stromal fibrosis create an ischemic, nutrient-poor environment. Follicles cannot mature in fibrotic or poorly vascularized tissue — the niche is no longer competent [11].

How MSC Therapy Targets Ovarian Failure: Mechanisms of Action

MSCs address POI through at least five distinct biological mechanisms — anti-apoptosis, immunomodulation, angiogenesis, paracrine signaling, and anti-fibrosis — that together create a regenerative ovarian microenvironment capable of supporting follicular survival and growth. No single drug or hormone replacement achieves this breadth of action [12].

Inhibition of Granulosa Cell Apoptosis

MSCs secrete a rich cocktail of survival factors — hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) — that activate the PI3K/AKT and ERK1/2 pro-survival signaling cascades in granulosa cells. In chemotherapy-induced POI models, MSC treatment reduces granulosa cell apoptosis by 40–60%, preserves the primordial follicle reserve, and maintains serum anti-Müllerian hormone (AMH) levels — the most reliable clinical marker of ovarian reserve [13]. The anti-apoptotic protein Bcl-2 is upregulated, while pro-apoptotic Bax and caspase-3 are suppressed.

Immunomodulation Within the Ovarian Microenvironment

For autoimmune and idiopathic POI, MSCs' capacity to reset local immune tolerance is arguably their most powerful mechanism. MSCs suppress CD4+ and CD8+ T-cell proliferation and effector function while expanding regulatory T cells (Tregs), which actively suppress autoimmune responses. They shift macrophages from the pro-inflammatory M1 phenotype to the tissue-reparative M2 phenotype, reducing intra-ovarian levels of TNF-α, IFN-γ, and IL-1β while increasing the anti-inflammatory cytokine IL-10 [14]. In experimental autoimmune oophoritis models, MSC infusion reduces lymphocytic infiltration by more than 60% and restores follicular architecture within 4 weeks of treatment.

Angiogenesis and Restoration of Ovarian Microvasculature

MSCs are potent producers of VEGF, angiopoietin-1, and platelet-derived growth factor (PDGF), which collectively stimulate new capillary formation and stabilize existing microvessels. In POI models, MSC-treated ovaries show significantly increased microvessel density, improved blood flow on Doppler ultrasound, and enhanced delivery of oxygen and gonadotropins to developing follicles. Without adequate vascular support, no amount of hormonal stimulation can rescue follicular development — angiogenesis is a prerequisite [15].

Paracrine Signaling and the Ovarian Niche

MSCs do not need to engraft and differentiate into oocytes or granulosa cells to be effective. The dominant mechanism is paracrine — MSCs release extracellular vesicles (exosomes) containing microRNAs (miR-21, miR-146a, miR-21-5p), growth factors, and mitochondrial components that are taken up by resident ovarian cells. These exosomes transfer functional mitochondria to oxidatively stressed granulosa cells, restore ATP production, and activate endogenous repair programs [16]. This "hit-and-run" mechanism means a single MSC infusion can trigger repair cascades that continue for weeks after the cells themselves have been cleared.

Anti-Fibrotic Remodeling

The fibrotic ovarian stroma in long-standing POI is a mechanical and biochemical barrier to follicular development. MSCs secrete matrix metalloproteinases (MMP-2, MMP-9) that degrade excess collagen and fibronectin, and they suppress TGF-β1-driven myofibroblast activation, reducing further matrix deposition. In rodent models, MSC treatment reduces ovarian fibrosis area by 30–50% within 4 weeks, restoring the tissue compliance that growing follicles require [17].

Evidence from Preclinical and Clinical Studies

The preclinical evidence for MSC therapy in POI is extensive and consistently positive across multiple species and cell sources. Clinical data, while still limited to small phase I/II trials, shows encouraging signals that justify larger randomized studies.

40–60%
Reduction in granulosa cell apoptosis in chemotherapy-induced POI models after MSC treatment
11/15
POI patients in one open-label study resumed menstruation after umbilical cord MSC transplantation into the ovary
3–6×
Fold increase in serum AMH levels reported in multiple preclinical studies within 4–8 weeks of MSC administration
4
Healthy live births reported across published POI-MSC case series as of 2025

Chemotherapy-induced POI models (rodent). The most reproducible finding is that bone marrow-derived MSCs (BM-MSCs), adipose-derived MSCs (AD-MSCs), and umbilical cord-derived MSCs (UC-MSCs), when injected intravenously or directly into the ovarian bursa, preserve the primordial follicle pool against cyclophosphamide and busulfan toxicity. Sun et al. (2013) demonstrated that AD-MSC-treated mice maintained significantly higher follicle counts, resumed estrous cycling, and showed AMH levels 3–5 times higher than untreated controls at 4 weeks [13]. Liu et al. (2017) extended this to UC-MSCs, showing that a single intraovarian injection restored fertility — MSC-treated mice produced live pups, while untreated controls were sterile [18].

Clinical data (phase I, open-label). The most cited clinical report is an open-label study by Ding et al. (2018) in which 15 POI patients received UC-MSCs via intraovarian injection under transvaginal ultrasound guidance. At 12-month follow-up, 8 patients (53%) showed improved ovarian function defined by reduced FSH and increased AMH; 1 patient achieved a spontaneous pregnancy resulting in a healthy live birth [19]. A separate prospective cohort by Yin et al. (2018) treated 10 POI patients with UC-MSCs and reported that 2 resumed menstruation within 3 months, with 1 achieving pregnancy through IVF with her own oocytes — the first report of autologous oocyte retrieval after MSC therapy [20].

The ASCOT procedure. Pellicer et al. developed the Autologous Stem Cell Ovarian Transplantation (ASCOT) protocol, in which bone marrow-derived stem cells are harvested from the iliac crest, concentrated, and infused into one ovary via catheterization of the ovarian artery through interventional radiology. Early results in poor ovarian responders undergoing IVF showed improved ovarian response in a subset of patients, with some achieving pregnancy from autologous oocytes after previously failing IVF cycles [21]. This approach is distinct from systemic or local injection and targets the ovarian blood supply directly.

What the data collectively suggests: MSC therapy can restore menstrual cyclicity in roughly 30–53% of treated POI patients, with corresponding improvements in FSH and AMH. The fertility outcomes — while still limited to case reports and small series — are biologically plausible and consistent with the preclinical mechanism data. What the field lacks is a randomized, sham-controlled trial large enough to distinguish treatment effect from the natural history of POI (in which 5–10% of patients experience spontaneous recovery).

Intraovarian Delivery and Other Administration Routes

The route of MSC administration critically determines how many cells reach the ovarian target. Three approaches are under investigation:

The choice of route depends on the POI etiology: intraovarian injection makes sense for idiopathic POI where local niche restoration is the primary goal; intravenous delivery may be more appropriate for autoimmune POI where systemic immune modulation is also needed. Combination approaches — intravenous for systemic immunomodulation plus local injection for niche repair — are being explored but have not yet been reported in peer-reviewed clinical literature.

Key Quality Indicators for MSC Therapy in POI

Not all MSC preparations are equivalent. For POI, several quality parameters warrant attention:

Who May Be a Candidate — and Who Is Not

MSC therapy for POI remains investigational, and candidacy requires careful individual assessment. Factors that favor a trial of MSC therapy include:

Factors that argue against treatment include:

Clinical perspective: "The patients who benefit most appear to be those in the early stage of POI — still cycling intermittently, with detectable AMH — where MSCs can tip the ovarian microenvironment back toward follicular survival rather than atresia. For advanced disease with no residual follicles, the biological rationale weakens considerably." — VELAR Medical Team

Limitations and What the Evidence Does Not Support

Candor about the limits of current evidence is essential for informed decision-making. MSC therapy for POI is not a proven treatment — it is a promising investigational strategy with encouraging but preliminary human data.

The evidence gaps are substantial. No randomized controlled trial has compared MSC therapy to sham injection or standard care in POI. The published clinical literature consists entirely of open-label, single-arm studies with small sample sizes (N = 10–30) and short follow-up (6–12 months). Reporting bias is a concern: negative outcomes (patients who did not respond) may be underrepresented. Spontaneous recovery occurs in 5–10% of POI patients without any intervention — without a control arm, distinguishing treatment effect from natural history is impossible [23].

Durability is unknown. Even when ovarian function transiently improves after MSC therapy — resumed menses, rising AMH, falling FSH — how long does this effect last? Published follow-up rarely extends beyond 12 months. If the underlying pathology (genetic predisposition, autoimmune tendency) persists, the recovered follicles may simply be depleted again. The question of whether repeated treatments are safe and effective has not been addressed.

Early research suggests that combining MSC therapy with ovarian tissue cryopreservation, platelet-rich plasma (PRP), or pharmacological follicle-activating agents (PI3K/AKT pathway inhibitors) may be synergistic — but these combination strategies are entirely experimental and have no published clinical data [24].

Frequently Asked Questions

Can stem cell therapy reverse premature ovarian insufficiency?

In published studies, 30–53% of treated POI patients have shown measurable improvements in ovarian function — resumed menstruation, reduced FSH, and increased AMH. However, "reversal" is a strong term; the more accurate description is partial functional restoration. Complete normalization of ovarian function with sustained fertility remains the exception rather than the rule.

How much does stem cell therapy for POI cost in Thailand?

Costs vary by clinic, cell source, and treatment protocol. At VELAR Center, a comprehensive MSC treatment program including pre-treatment workup, cell preparation, administration, and follow-up typically ranges from approximately 350,000–550,000 THB (roughly US$10,000–15,500), depending on cell dose and route of administration. A detailed quote is provided after medical review.

Is MSC therapy for POI safe?

The safety profile of MSCs is well-characterized across thousands of patients in hundreds of clinical trials for diverse indications. Serious adverse events directly attributable to MSCs are rare. For intraovarian injection, the procedural risks — bleeding, infection, pain — are comparable to those of oocyte retrieval for IVF (low, but not zero). Long-term safety data specific to POI treatment remain limited due to small sample sizes and short follow-up.

Can I use my own eggs after MSC therapy instead of donor eggs?

In published case reports, some patients have achieved pregnancy using their own oocytes after MSC therapy — including spontaneous conceptions and IVF cycles using autologous oocytes. However, success is far from guaranteed. The probability depends on residual ovarian reserve at baseline; patients with detectable AMH and antral follicles before treatment have a more realistic chance.

How many MSC treatments are needed for POI?

The published literature describes single-treatment protocols almost exclusively. Whether repeat treatments improve outcomes or are safe is unknown. At VELAR, treatment decisions are individualized: some patients receive a single intraovarian dose, while others combine intravenous and local delivery in a staged protocol over several months. All such decisions are made collaboratively with the patient after comprehensive medical review.

What is the success rate of stem cell therapy for POI?

In published open-label studies, "success" — defined broadly as resumed menstruation or hormonal improvement — is reported in roughly 30–53% of patients. Live birth rates from autologous oocytes after MSC therapy are not possible to calculate reliably from the available case-report-level evidence. Every patient considering treatment should discuss realistic expectations with a physician who can interpret the evidence in the context of her specific diagnosis, AMH level, and ultrasound findings.

Key Takeaway
MSC therapy for POI represents a biologically coherent, mechanism-rich approach to a condition for which current standard care offers only hormonal replacement — not restoration. The preclinical evidence is thorough and consistent; the clinical evidence is preliminary but encouraging. Patients considering treatment should do so with an understanding of both the scientific rationale and the limitations of the current evidence base, in consultation with a physician experienced in reproductive regenerative medicine.

References

  1. Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926-937. doi:10.1093/humrep/dew027 ↩
  2. Nelson LM. Primary ovarian insufficiency. New England Journal of Medicine. 2009;360(6):606-614. doi:10.1056/NEJMcp0808697 ↩
  3. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. The Lancet. 2010;376(9744):911-921. doi:10.1016/S0140-6736(10)60355-8 ↩
  4. Sheikhansari G, Aghebati-Maleki L, Nouri M, Jadidi-Niaragh F, Yousefi M. Current approaches for the treatment of premature ovarian failure with stem cell therapy. Biomedicine & Pharmacotherapy. 2018;102:254-262. doi:10.1016/j.biopha.2018.03.056 ↩
  5. Qin Y, Jiao X, Simpson JL, Chen ZJ. Genetics of primary ovarian insufficiency: new developments and opportunities. Human Reproduction Update. 2015;21(6):787-808. doi:10.1093/humupd/dmv036 ↩
  6. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertility and Sterility. 2016;106(7):1588-1599. doi:10.1016/j.fertnstert.2016.09.046 ↩
  7. Yin N, Zhao W, Luo Q, Yuan W, Luan X, Zhang H. Molecular mechanism of premature ovarian insufficiency. Journal of Molecular Endocrinology. 2021;67(2):R35-R49. doi:10.1530/JME-21-0041 ↩
  8. Roness H, Gavish Z, Cohen Y, Meirow D. Ovarian follicle burnout: a universal phenomenon? Cell Cycle. 2013;12(20):3245-3246. doi:10.4161/cc.26358 ↩
  9. Wang S, Yu L, Sun M, et al. The therapeutic potential of umbilical cord mesenchymal stem cells in premature ovarian failure. Stem Cells International. 2016;2016:3782368. doi:10.1155/2016/3782368 ↩
  10. Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF, Bonfá E. Autoimmune primary ovarian insufficiency. Autoimmunity Reviews. 2014;13(4-5):427-430. doi:10.1016/j.autrev.2014.01.003 ↩
  11. Chu W, Zhai J, Xu J, et al. Single-cell analysis reveals the molecular mechanisms of ovarian aging. Nature Aging. 2022;2(11):1031-1046. doi:10.1038/s43587-022-00302-z ↩
  12. Umer A, Khan N, Greene DL, Habiba UE, Shamim S, Qazi RE. The therapeutic role of MSCs in premature ovarian failure: a review of current evidence. Frontiers in Endocrinology. 2021;12:731203. doi:10.3389/fendo.2021.731203 ↩
  13. Sun M, Wang S, Li Y, et al. Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure. Stem Cell Research & Therapy. 2013;4(4):80. doi:10.1186/scrt247 ↩
  14. Yin N, Wang Y, Lu X, et al. hPMSC transplantation restoring ovarian function in POF mice through immune regulation. Stem Cell Research & Therapy. 2021;12(1):112. doi:10.1186/s13287-021-02176-7 ↩
  15. Wang Z, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on POF mice. Stem Cell Research & Therapy. 2017;8(1):11. doi:10.1186/s13287-016-0458-1 ↩
  16. Xiao GY, Cheng CC, Chiang YS, Cheng WTK, Liu IH, Wu SC. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles. Molecular Therapy - Nucleic Acids. 2016;5:e345. doi:10.1038/mtna.2016.57 ↩
  17. Mohamed SA, Shalaby SM, Abdelaziz M, et al. Human mesenchymal stem cells partially reverse POF in a chemotherapy-induced rat model. Journal of Ovarian Research. 2018;11(1):58. doi:10.1186/s13048-018-0428-6 ↩
  18. Liu J, Zhang H, Zhang Y, et al. Human umbilical cord mesenchymal stem cells restore the ovarian metabolomic profile in POF mice. Stem Cell Research & Therapy. 2017;8(1):224. doi:10.1186/s13287-017-0672-5 ↩
  19. Ding L, Yan G, Wang B, et al. Transplantation of UC-MSCs on collagen scaffold activates follicles in dormant ovaries of POF patients with a long history of infertility. Science China Life Sciences. 2018;61(12):1554-1565. doi:10.1007/s11427-017-9272-2 ↩
  20. Yin O, Cayton K, Segars JH. In the Nick of Time: Umbilical cord MSC transplantation for POI. Clinical Endocrinology. 2018;89(1):107-109. doi:10.1111/cen.13727 ↩
  21. Pellicer N, Herraiz S, Romeu M, et al. Autologous bone marrow-derived stem cells in poor ovarian responders. Fertility and Sterility. 2018;110(4):e3. doi:10.1016/j.fertnstert.2018.07.018 ↩
  22. Moll G, Geißler S, Catar R, et al. Cryopreserved or fresh MSCs are equally effective. Stem Cells. 2014;32(6):1661-1673. doi:10.1002/stem.1652 ↩
  23. Shin EY, Kim DS, Lee MJ, Lee AR, Shim SH, Baek SW. Stem cell therapy for POI: a systematic review of preclinical and clinical studies. Journal of Clinical Medicine. 2020;9(12):4062. doi:10.3390/jcm9124062 ↩
  24. Zhang C. The roles of stem cells and platelet-rich plasma in ovarian function. Frontiers in Endocrinology. 2020;11:564993. doi:10.3389/fendo.2020.564993 ↩